Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Docetaxel in Hormone Refractory Prostate Cancer
NCT00183937Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Apr 2005
- Primary completion
- Oct 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in prostate cancer (PCa), sponsored by University of Southern California. Primary endpoint: Prostate Specific Antigen Response Rate. Started Apr 2005; status: terminated.
02
Drugs
bortezomib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00183937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183937.